- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
Michael S. Leapman, MD, MHS
Biography
Michael S. Leapman, MD, who specializes in prostate, bladder, testicular and kidney cancers, loves his work as a urologic oncologist.
“Every day, I have the ability to make a difference in a patient's life,” says Dr. Leapman. “It's a tremendous honor and responsibility, and it's very rewarding.”
A member of Yale Cancer Center, he sees patients at Smilow Cancer Hospital and the West Haven Veteran’s Administration. An assistant professor of urology at Yale School of Medicine, he studies the best treatments for prostate cancer and how gene expression signatures can predict the aggressiveness of this cancer.
“Hearing the emotionally wrought words ‘it’s cancer’ is extremely difficult to navigate,” he says. “So that's one of the issues that we are sensitive to, and continue to strive to improve.”
The patient-physician bond is essential in helping patients with prostate cancer, for example, to choose which kind of treatment is best: surgery, radiation therapy or active surveillance, an ongoing monitoring of what can be a slow-progressing disease.
“It really is a very special relationship between a urologist and a patient. I have found that the team at Yale is 100 percent invested in the outcomes of our patients, and we stand out by seeking to understand their concerns, goals by being there for them every step of the way.”
Titles
- Associate Professor of Urology
- Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
- Assistant Professor, Chronic Disease Epidemiology
Education & Training
- MHSYale University (2022)
- FellowshipUniversity of California San Francisco (2016)
- ResidencyMount Sinai Medical Center (2014)
- InternshipMount Sinai Medical Center (2010)
- MDUniversity of Maryland School of Medicine (2009)
- BACornell University (2005)
Additional Information
- John N. Forrest Jr. Prize for Mentorship in Student Research: (2022)
- Best Poster: European School of Oncology, Conference on Active Surveillance (2016)
- Merit Award: Conquer Cancer Foundation of the American Society of Clinical Oncology (2015)
- First Place Essay, History Section: American Urological Association Western Section (2015)
- Joseph F. McCarthy Physician Essay Contest, Third Place: American Urological Association Western Section (2015)
- Outstanding Abstract Selected for Oral Presentation: University of California San Francisco (2015)
- Resident Publication Award: Mount Sinai Medical Center, Department of Urology (2014)
- Resident Travel Award: Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (2013)
- AB of Urology, Urology (2018)
- Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. DOI: 10.37349/etat.2024.00269.
- Rabil M, Leapman M, Cavallo J. Reply to Editorial Comment on "Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy". Urology 2024 PMID: 39208938, DOI: 10.1016/j.urology.2024.08.054.
- Forman R, Long J, Westvold S, Agnish K, Mcmanus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.
- Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.
- Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.
- Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 101097upj0000000000000679. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy. Urology 2024 PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.
- Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024 PMID: 38959160, DOI: 10.1089/sur.2024.107.
- Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-Insured Patients with Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024 PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.
- Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.
- Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.
- Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Leapman M, Cavallo J. MP33-06 ASSOCIATION BETWEEN CROWD-SOURCED ASSESSMENT OF TECHNICAL SKILLS (CSATSTM) AND COMPLICATIONS FOLLOWING RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e562. DOI: 10.1097/01.ju.0001009520.30626.80.06.
- Rabil M, Jalfon M, Heckscher D, Kong V, Golos A, Richmond R, Chess A, Leapman M, Cavallo J. MP02-19 AUTOMATED ABSTRACTION ALGORITHM FOR RADICAL PROSTATECTOMY SURGICAL OUTCOMES. Journal Of Urology 2024, 211: e20. DOI: 10.1097/01.ju.0001008600.97797.3b.19.
- Lokeshwar S, Choksi A, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Brito J, Renzulli J, Leapman M. MP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e947. DOI: 10.1097/01.ju.0001008852.83523.41.01.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- Webb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- Golos A, Nie J, Hsiang W, Davies B, Filson C, Leapman M. MP24-10 TRENDS IN UROLOGY PRACTICE CONSOLIDATION AND PRIVATE EQUITY INVESTMENT FROM 2011-2023. Journal Of Urology 2024, 211: e396. DOI: 10.1097/01.ju.0001008860.46052.c4.10.
- Lokeshwar S, Shaheen D, Choksi A, Patel M, Rahman S, Martin T, Hesse D, Leapman M. HF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE. Journal Of Urology 2024, 211: e282. DOI: 10.1097/01.ju.0001008828.35887.de.10.
- Sutherland R, Golos A, Leapman M. PD40-09 “WHAT DO YOU MEAN BY a ‘RISK’? I’D LIKE TO SEE THAT PRESENTED BETTER”: A QUALITATIVE STUDY EXPLORING PATIENT PREFERENCES ABOUT PROSTATE CANCER RISK ASSESSMENT AND COMMUNICATION. Journal Of Urology 2024, 211: e823. DOI: 10.1097/01.ju.0001009356.04608.d5.09.
- Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.
- Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.
- Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
- Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.
- Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.
- Heckscher D, Jalfon M, Buck M, Abello A, Nguyen J, Casilla-Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Kenney P, Cavallo J, Lambert S. Implementation of a health system intervention to reduce time from presentation to surgical intervention for pediatric testicular torsion. Journal Of Pediatric Urology 2023, 20: 254.e1-254.e7. PMID: 38030428, DOI: 10.1016/j.jpurol.2023.10.042.
- Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.
- Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.
- Leapman M. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care. Urology Practice 2023, 11: 7-8. PMID: 37747948, DOI: 10.1097/upj.0000000000000459.
- Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancerLeapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.
- Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.
- Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Jalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.
- Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.
- Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.
- Smani S, Novosel M, Marks V, Jeong F, Sprenkle P, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Journal Of Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENT. Journal Of Urology 2023, 209: e586. DOI: 10.1097/ju.0000000000003286.07.
- Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
- Esmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
- Laditi F, Nie J, Marks V, Leapman M. MP77-14 PATIENT AND FACILITY FACTORS ASSOCIATED WITH 90-DAY MORTALITY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2023, 209: e1107. DOI: 10.1097/ju.0000000000003351.14.
- Laditi F, Nie J, Hsiang W, Umar W, Haleem A, Marks V, Buck M, Leapman M. MP75-07 ACCESS TO UROLOGIC CANCER CARE FOR MEDICAID-INSURED PATIENTS. Journal Of Urology 2023, 209: e1081. DOI: 10.1097/ju.0000000000003349.07.
- Leapman M, Loeb S, Cooperberg M, Catalona W, Gaylis F. A vision for closing the evidence-practice gap in the management of low-grade prostate cancer. JNCI Cancer Spectrum 2023, 7: pkad028. PMID: 37101361, PMCID: PMC10133397, DOI: 10.1093/jncics/pkad028.
- Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2023, 41: 610-610. DOI: 10.1200/jco.2023.41.6_suppl.610.
- Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.
- Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.
- Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.
- Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.
- Laditi F, Nie J, Hsiang W, Umer W, Haleem A, Marks V, Buck M, Leapman M. Access to urologic cancer care for Medicaid-insured patients. Urologic Oncology Seminars And Original Investigations 2023, 41: 206.e21-206.e27. PMID: 36740488, DOI: 10.1016/j.urolonc.2023.01.014.
- Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.
- Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology 2023, 83: 463-471. PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.
- Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.
- Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.
- Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.
- Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.
- Nabavizadeh B, Li KD, Hakam N, Shaw NM, Leapman MS, Breyer BN. Incidence of circumcision among insured adults in the United States. PLOS ONE 2022, 17: e0275207. PMID: 36251658, PMCID: PMC9576047, DOI: 10.1371/journal.pone.0275207.
- Marks VA, Hsiang WR, Nie J, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Berger ER, Boffa DJ, Leapman MS. Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis. JAMA Network Open 2022, 5: e2222214. PMID: 35838668, PMCID: PMC9287756, DOI: 10.1001/jamanetworkopen.2022.22214.
- Leapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
- Rahman S, Syed J, Lokeshwar S, Press B, Monaghan T, Leapman M. MP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT. Journal Of Urology 2022, 207: e680. DOI: 10.1097/ju.0000000000002600.14.
- Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Overcash M, Sherman J. MP30-14 ENVIRONMENTAL IMPACT OF TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY. Journal Of Urology 2022, 207: e483. DOI: 10.1097/ju.0000000000002573.14.
- Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
- Khajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Journal Of Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
- Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.
- Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Holler J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice 2021, 9: 56-63. PMID: 37145560, DOI: 10.1097/upj.0000000000000275.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Reply by Authors. Urology Practice 2021, 9: 24-24. PMID: 37145588, DOI: 10.1097/upj.0000000000000269.02.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Urology Practice Acquisitions by Private Equity Firms from 2011–2021. Urology Practice 2021, 9: 17-24. PMID: 37145557, DOI: 10.1097/upj.0000000000000269.
- Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.
- Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.
- Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRI. Journal Of Urology 2021, 206: e751-e751. DOI: 10.1097/ju.0000000000002060.08.
- Fero K, Lec P, Sharma V, Lenis A, Low J, Litwin M, Leapman M, Chamie K. MP40-13 WHEN IS A SEMINOMA NOT A SEMINOMA? THE INCIDENCE, RISK FACTORS AND MANAGEMENT OF PATIENTS WITH TESTICULAR SEMINOMA WITH DISCORDANT ELEVATED SERUM ALPHA-FETOPROTEIN. Journal Of Urology 2021, 206: e719-e719. DOI: 10.1097/ju.0000000000002055.13.
- Sharma V, Lec P, Fero K, Lenis A, Shirk J, Venkataramana A, Leapman M, Chamie K, Saigal C, Litwin M. MP40-10 TESTICULAR TUMOR SIZE IS ASSOCIATED WITH NONLOCALIZED DISEASE AT DIAGNOSIS. Journal Of Urology 2021, 206: e718-e718. DOI: 10.1097/ju.0000000000002055.10.
- Buck M, Nguyen J, Abello A, Leapman M, Cavallo J, Kenney P. PD38-07 ANTIBIOTIC PROPHYLAXIS PRIOR TO OUTPATIENT UROLOGIC PROCEDURES: OUTCOMES FROM A DEPARTMENT-WIDE QUALITY IMPROVEMENT PROJECT. Journal Of Urology 2021, 206: e664-e665. DOI: 10.1097/ju.0000000000002048.07.
- Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Paradysz A, Pradere B, Shariat S, Leapman M. MP67-24 ASSESSING ONLINE CROWDFUNDING FOR UROLOGIC CANCER CARE USING AUTOMATED DATA EXTRACTION. Journal Of Urology 2021, 206: e519-e519. DOI: 10.1097/ju.0000000000002028.24.
- Demkowicz P, Buck M, Nie J, Marks V, Leapman M. MP17-03 FACILITY-LEVEL FACTORS ASSOCIATED WITH DECREASING SHARE OF UROLOGIC CANCER PATIENTS WITH MEDICAID FOLLOWING IMPLEMENTATION OF THE AFFORDABLE CARE ACT. Journal Of Urology 2021, 206: e308-e309. DOI: 10.1097/ju.0000000000002002.03.
- Leapman M, Wang R, Gross C, Ma X. PD50-11 CHANGES IN PSA SCREENING RELATIVE TO THE REVISED USPSTF GUIDANCE FOR PROSTATE CANCER SCREENING. Journal Of Urology 2021, 206: e856-e856. DOI: 10.1097/ju.0000000000002072.11.
- Press B, Khajir G, Olawoyin O, Leapman M, Sprenkle P. MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSY. Journal Of Urology 2021, 206: e468-e468. DOI: 10.1097/ju.0000000000002023.14.
- Nguyen J, Buck M, Abello A, Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Cavallo J, Kenney P, Lambert S. PD38-10 AN INITIATIVE TO REDUCE DOOR TO INCISION TIME FOR PATIENTS WITH TESTICULAR TORSION. Journal Of Urology 2021, 206: e666-e666. DOI: 10.1097/ju.0000000000002048.10.
- Lokeshwar S, Syed J, Amin J, Merenda C, Leapman M, Weiss R. HF02-11 DR. CLYDE LEROY DEMING: VISIONARY DURING A TURBULENT TIME. Journal Of Urology 2021, 206: e240-e240. DOI: 10.1097/ju.0000000000001993.11.
- Segal D, Drew I, Buck M, Grimshaw A, Cavallo J, Leapman M. HF01-14 ANALYSIS OF ETIOLOGIC THEORIES PROPOSED TO EXPLAIN RACIAL DISPARITY IN PROSTATE CANCER OUTCOMES: A SCOPING REVIEW. Journal Of Urology 2021, 206: e232-e233. DOI: 10.1097/ju.0000000000001992.14.
- Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Paradysz A, Pradere B, Shariat S, Leapman M. P0977 Assessing online crowdfunding for urologic cancer care using automated data extraction. European Urology 2021, 79: s1377. DOI: 10.1016/s0302-2838(21)01350-6.
- Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.
- Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.
- Marks V, Hsiang W, Nie J, Buck M, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Access to cancer care for Medicaid patients at cancer hospitals in the United States. Journal Of Clinical Oncology 2021, 39: 6548-6548. DOI: 10.1200/jco.2021.39.15_suppl.6548.
- Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Accessibility of Telehealth services for cancer care at cancer hospital in the United States. Journal Of Clinical Oncology 2021, 39: 6535-6535. DOI: 10.1200/jco.2021.39.15_suppl.6535.
- Miccio J, Talcott W, Jairam V, Park H, Yu J, Leapman M, King M, Nguyen P, Kann B. Quantifying Treatment Selection Bias Effects on Survival in National Database Studies: Findings from Low-Risk Prostate Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e397. DOI: 10.1016/j.ijrobp.2020.07.2439.
- Abello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
- Abello A, Renzulli J, Park H, Leapman M, Kenney P. PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer. European Urology Open Science 2020, 19: e2283. DOI: 10.1016/s2666-1683(20)34148-3.
- Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.
- Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.
- Hsiang* W, Elftmann E, Honig S, Leapman M. PD28-04 EVALUATION OF ONLINE TELEHEALTH PLATFORMS FOR DIRECT-TO-CONSUMER TREATMENT OF ERECTILE DYSFUNCTION. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000892.04.
- Leapman* M, Wang R, Ma X, Gross C. MP23-17 ASSOCIATIONS OF REGIONAL-LEVEL ADOPTION OF PROSTATE MRI AND GENOMIC TESTING AND OBSERVATION FOR PROSTATE CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000856.017.
- Abello* A, Nawaf C, Renzulli J, Park H, Leapman M, Kenney P. PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000965.02.
- Abello* A, Nawaf C, Leapman M, Kenney P. MP68-05 CLINICAL OUTCOMES OF LOW-STAGE SARCOMATOID RENAL CELL CARCINOMA. Journal Of Urology 2020, 203: e1036. DOI: 10.1097/ju.0000000000000948.05.
- Abello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
- Hsiang* W, Yousman L, Leapman M. MP12-17 ASSOCIATION OF INSURANCE STATUS AND ACCESS TO UROLOGICAL CARE AT URGENT CARE CENTERS. Journal Of Urology 2020, 203: e151. DOI: 10.1097/ju.0000000000000832.017.
- Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
- Advani S, Gao C, Datta R, Sann L, Smith C, Leapman MS, Hittelman A, Sabetta J, Dembry LM, Martinello RA, Juthani-Mehta M. Knowledge and Practices of Physicians and Nurses related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines. Open Forum Infectious Diseases 2019, 6: ofz305. PMID: 31375836, PMCID: PMC6677670, DOI: 10.1093/ofid/ofz305.
- Mehal W, Secor E, Weiss T, Fields M, Leapman M, Ali A. Isoflavone Stability Quality Control Assessment of Q-CAN® Plus, a Novel Fermented Soy Beverage (P12-034-19). Current Developments In Nutrition 2019, 3: 3013530. PMCID: PMC6574992, DOI: 10.1093/cdn/nzz035.p12-034-19.
- Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.
- Abello* A, Syed J, Leapman M, Kenney P. MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOME. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557554.82490.aa.
- Hsiang W, Jemal A, Nguyen K, Shuch B, Park H, Yu J, Gross C, Davidoff A, Leapman* M. MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557551.36748.5c.
- Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
- Syed* J, Abello A, Javier-DesLoges J, Leapman M, Kenney P. PD58-05 UROLOGIC MALIGNANCIES: A COMPARISON OF OUTCOMES AFTER INDEX SURGERY BETWEEN ACADEMIC AND COMMUNITY HOSPITALS. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557173.74355.7e.
- Abello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
- Yang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
- Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.
- Syed J, Abello A, Javier-Desloges J, Leapman M, Kenney P. Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals. Journal Of Clinical Oncology 2019, 37: 489-489. DOI: 10.1200/jco.2019.37.7_suppl.489.
- Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.
- Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.
- Abello A, Kenney P, Leapman M. Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy. Journal Of Clinical Oncology 2019, 37: 284-284. DOI: 10.1200/jco.2019.37.7_suppl.284.
- Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate CancerLeapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.
- Javier-DesLoges J, Amirkhiz K, Su J, Kenney P, Advani S, Hittelman A, Leapman M. MP80-02 LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTION. Journal Of Urology 2018, 199: e1089. DOI: 10.1016/j.juro.2018.02.2690.
- Masic S, Nguyen H, Cowan J, Leapman M, Carroll P. PD38-10 IMPACT OF LYMPH NODE COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN NODE POSITIVE PATIENTS WITH PROSTATE CANCER. Journal Of Urology 2018, 199: e740. DOI: 10.1016/j.juro.2018.02.1757.
- Hsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Journal Of Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
- Leapman M, Wang R, Park H, Yu J, Gross C, Ma X. MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT. Journal Of Urology 2018, 199: e707. DOI: 10.1016/j.juro.2018.02.1679.
- Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
- Amirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
- Amirkhiz K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. PD42-01 NATIONAL TRENDS IN THE MANAGEMENT OF PATIENTS WITH POSITIVE SURGICAL MARGINS AT THE TIME OF RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e814. DOI: 10.1016/j.juro.2018.02.1954.
- Lu A, Amirkhiz K, Nguyen K, Hsiang W, Leapman M. MP34-07 DISPARITIES IN THE DIAGNOSIS AND MANAGEMENT OF METASTATIC PROSTATE CANCER IN YOUNG MEN. Journal Of Urology 2018, 199: e440. DOI: 10.1016/j.juro.2018.02.1099.
- Nguyen K, Nolte A, Alimi O, Hsiang W, Syed J, Suarez-Sarmiento A, Lu A, Ghabili K, Shuch B, Leapman M. PD51-06 DETERMINANTS OF ACTIVE SURVEILLANCE IN PATIENTS WITH SMALL RENAL MASSES. Journal Of Urology 2018, 199: e977-e978. DOI: 10.1016/j.juro.2018.02.2346.
- Su J, Javier-DesLoges J, Leapman M. MP51-09 EXAMINING POST-OPERATIVE OPIOID PRESCRIBING PATTERNS FOLLOWING UROLOGIC SURGERY USING AN ENTERPRISE-WIDE ELECTRONIC MEDICAL RECORD. Journal Of Urology 2018, 199: e688. DOI: 10.1016/j.juro.2018.02.1640.
- Nguyen K, Hsiang W, Syed J, Nolte A, Lu A, Suarez-Sarmiento A, Ghabili K, Shuch B, Leapman M. MP10-14 INCIDENCE, RISK FACTORS, AND OUTCOMES OF C. DIFFICILE INFECTION FOLLOWING RADICAL CYSTECTOMY: A NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (NSQIP) STUDY. Journal Of Urology 2018, 199: e122. DOI: 10.1016/j.juro.2018.02.360.
- Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e1066. DOI: 10.1016/j.juro.2018.02.2644.
- Lu A, Nguyen K, Nolte A, Alimi O, Hsiang W, Ghabili K, Syed J, Shuch B, Leapman M. National determinants of active surveillance among patients with clinical stage 1A kidney tumors. Journal Of Clinical Oncology 2018, 36: 694-694. DOI: 10.1200/jco.2018.36.6_suppl.694.
- Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
- Ghabili K, Nguyen K, Lu A, Hsiang W, Shuch B, Leapman M. Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 144-144. DOI: 10.1200/jco.2018.36.6_suppl.144.
- Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
- Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.
- Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
- Ghabili K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. National trends in the management of patients with positive surgical margins at the time of radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 111-111. DOI: 10.1200/jco.2018.36.6_suppl.111.
- Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLOS ONE 2017, 12: e0185535. PMID: 29016610, PMCID: PMC5634556, DOI: 10.1371/journal.pone.0185535.
- Nguyen K, Gross C, Cooperberg M, Katz M, Hittelman A, Syed J, Schulam P, Leapman M. MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT? Journal Of Urology 2017, 197: e928-e929. DOI: 10.1016/j.juro.2017.02.2303.
- Eapen R, Washington S, Sanford T, Leapman M, Meng M, Porten S. MP10-13 IMPACT OF HISTOLOGIC SUBTYPE ON BLADDER CANCER OUTCOME. Journal Of Urology 2017, 197: e113. DOI: 10.1016/j.juro.2017.02.341.
- Nguyen H, Westphalen A, Niloufar A, Leapman M, Cowan J, Simko J, Shinohara K, Carroll P. PD65-11 DOES PI-RADS V2 SCORES PREDICT ADVERSE SURGICAL PATHOLOGY AT RADICAL PROSTATECTOMY? Journal Of Urology 2017, 197: e1270. DOI: 10.1016/j.juro.2017.02.2961.
- Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.
- Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.
- Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer OutcomesLeapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.
- Leapman M, Carroll P. Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. Urology Practice 2016, 4: 322-328. PMID: 37592678, DOI: 10.1016/j.urpr.2016.06.008.
- Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.
- Eltemamy M, Leapman M, Cowan J, Shinohara K, Westphalen A, Carroll P. MP15-07 SERIAL ANATOMIC PROSTATE ULTRASOUND IMAGING DURING PROSTATE CANCER ACTIVE SURVEILLANCE. Journal Of Urology 2016, 195: e154. DOI: 10.1016/j.juro.2016.02.2531.
- Leapman M, Nguyen H, Cowan J, Porten S, Meng M, Cooperberg M, Carroll P. MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER. Journal Of Urology 2016, 195: e1043. DOI: 10.1016/j.juro.2016.02.2033.
- Leapman M, Wang Z, Behr S, Kurhanewicz J, Zagoria R, Carroll P, Guimarães C, Westphalen A. MP79-10 PROTON MAGNETIC RESONANCE IMAGING SPECTROSCOPY IMPROVES PREDICTION OF HIGH GRADE PROSTATE CANCER WHEN INTEGRATED IN PI-RADS 2. Journal Of Urology 2016, 195: e1038. DOI: 10.1016/j.juro.2016.02.2008.
- Leapman M, Nguyen H, Cowan J, Perez N, Shinohara K, Catalona W, Cooperberg M, Carroll P. PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER. Journal Of Urology 2016, 195: e56. DOI: 10.1016/j.juro.2016.02.2089.
- Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. MP79-11 EXTERNAL VALIDATION OF A PROGNOSTIC GLEASON GRADE CLASSIFICATION SYSTEM. Journal Of Urology 2016, 195: e1038-e1039. DOI: 10.1016/j.juro.2016.02.2009.
- Leapman M, Tran G, Nguyen H, Cowan J, Westphalen A, Shinohara K, Carroll P. MP15-19 FUSION MRI-ULTRASOUND BIOPSY DURING PROSTATE CANCER ACTIVE SURVEILLANCE. Journal Of Urology 2016, 195: e159. DOI: 10.1016/j.juro.2016.02.2543.
- Nguyen H, Leapman M, Punnen S, Cowan J, Cary C, Welty C, Cooperberg M, Meng M, Greene K, Porten S, Garcia M, Carroll P. PI-03 A RANDOMIZED STUDY OF INTRA-OPERATIVE AUTOLOGOUS RETROPUBIC URETHRAL SLING ON URINARY CONTROL AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY. Journal Of Urology 2016, 195: e409-e410. DOI: 10.1016/j.juro.2016.02.1208.
- Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Walker K, Amling C, Carroll P, Cooperberg M. PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACY. Journal Of Urology 2016, 195: e987-e988. DOI: 10.1016/j.juro.2016.02.1755.
- Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. External validation of a prognostic Gleason grade classification system. Journal Of Clinical Oncology 2016, 34: 123-123. DOI: 10.1200/jco.2016.34.2_suppl.123.
- Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.
- Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.
- Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.
- Nguyen H, Leapman M, Cowan J, Carroll P. Extended lymphadenectomy: A critical review. European Urology Open Science 2016, 15: 33-33c. DOI: 10.1016/s1569-9056(16)30007-0.
- Leapman M, Nguyen H, Cowan J, Carroll P. Are there any new reliable triggers in active surveillance? European Urology Open Science 2016, 15: 31-31b. DOI: 10.1016/s1569-9056(16)30005-7.
- Leapman M, Cooperberg M. Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined? 2016, 33-52. DOI: 10.1007/978-3-319-21485-6_3.
- Leapman M, Shinohara K. TRUS Biopsy: Is There Still a Role? 2016, 53-67. DOI: 10.1007/978-3-319-21485-6_4.
- Polland A, Leapman M, Stone N. A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate Cancer. 2015, 151-172. DOI: 10.1007/978-3-319-23817-3_11.
- Garcia M, Leapman M, Brajtbord J, Carroll P. PD15-12 DESIGN AND EARLY CLINICAL EXPERIENCE WITH A TACTILE FEEDBACK DRIVEN PELVIC FLOOR MUSCLE TRAINING SMARTPHONE APP. Journal Of Urology 2015, 193: e329. DOI: 10.1016/j.juro.2015.02.1329.
- Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo P, Cooperberg M, Carroll P. MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA). Journal Of Urology 2015, 193: e642-e643. DOI: 10.1016/j.juro.2015.02.1712.
- Leapman M, Crawford D, Poage W, Stone N. MP24-10 DECLINING USE OF URINARY HERBAL AND VITAMIN SUPPLEMENTS AMONG U.S. MEN IN LONGITUDINAL NATIONAL PROSTATE CANCER SCREENING COHORTS. Journal Of Urology 2015, 193: e279. DOI: 10.1016/j.juro.2015.02.1152.
- Leapman M, Shinohara K, Ameli N, Meng M, Cooperberg M, Carroll P. MP86-10 CLINICAL PROSTATE CANCER RISK PREDICTION DERIVED FROM TARGETED BIOPSY. Journal Of Urology 2015, 193: e1079. DOI: 10.1016/j.juro.2015.02.1919.
- Welty C, Leapman M, Brajtbord J, Cowan J, Cooperberg M, Carroll P. PD47-02 IMPROVED PRE-RADICAL PROSTATECTOMY RISK STRATIFICATION USING PSA DENSITY. Journal Of Urology 2015, 193: e961-e962. DOI: 10.1016/j.juro.2015.02.2746.
- Sagalovich D, Leapman M, Sfakianos J, Hall S, Stock R, Stone N. MP87-04 TIMING OF SALVAGE ANDROGEN DEPRIVATION THERAPY FOLLOWING PROSTATE RADIOTHERAPY DOES NOT ADVERSELY AFFECT ALL-CAUSE OR PROSTATE CANCER SPECIFIC SURVIVAL. Journal Of Urology 2015, 193: e1085. DOI: 10.1016/j.juro.2015.02.1949.
- Leapman M, Ameli N, Chu C, Hussein A, Welty C, Cooperberg M, Carroll P. MP42-12 CANCER OF THE PROSTATE RISK ASSESSMENT SCORE FOLLOWING BIOPSY GLEASON UPGRADE DURING PROSTATE CANCER ACTIVE SURVEILLANCE IS ASSOCIATED WITH ADVERSE PATHOLOGY AT PROSTATECTOMY. Journal Of Urology 2015, 193: e513. DOI: 10.1016/j.juro.2015.02.1597.
- Leapman M, Westphalen A, Ameli N, Lawrence H, Febbo P, Cooperberg M, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal Of Clinical Oncology 2015, 33: 83-83. DOI: 10.1200/jco.2015.33.7_suppl.83.
- Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.
- Kwon Y, Mcbride R, Leapman M, Katsigeorgis M, Collingwood S, Hobbs A, Samadi D. P046 The modulating effects of benign prostate hyperplasia medications on upgrading predictors. European Urology Open Science 2014, 13: 126. DOI: 10.1016/s1569-9056(14)61269-0.
- Collingwood S, Kwon Y, Hobbs A, Katsigeorgis M, Mcbride R, Leapman M, Samadi D. P045 The quality of nerve-sparing during radical prostatectomy affects sexual function and urinary continence recovery. European Urology Open Science 2014, 13: 125. DOI: 10.1016/s1569-9056(14)61268-9.
- Leapman M, Stock J. FRII-05 FIVE DECADES OF UROLOGIC INVESTIGATION IN MICROGRAVITY. Journal Of Urology 2014, 191: e628-e629. DOI: 10.1016/j.juro.2014.02.1743.
- Leapman M, Jayadevan R, Phillips C, Hall S, Palese M, Fischman A. V5-14 PERCUTANEOUS GAS-COOLED MICROWAVE ABLATION FOR SMALL RENAL MASSES: THE MOUNT SINAI EXPERIENCE. Journal Of Urology 2014, 191: e620. DOI: 10.1016/j.juro.2014.02.1717.
- Leapman M, Stone N. Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer. Current Bladder Dysfunction Reports 2013, 8: 236-241. DOI: 10.1007/s11884-013-0188-5.
- Leapman M, Stock J. 1115 CIRCUMCISION REVERSAL: ANTIQUITY AND THE DEFICIENT PREPUCE. Journal Of Urology 2013, 189: e456. DOI: 10.1016/j.juro.2013.02.707.
- Leapman M, Stone N, Mock S, Hall S, Stock R. 1203 PREDICTORS OF URINARY INCONTINENCE FOLLOWING PROSTATE BRACHYTHERAPY. Journal Of Urology 2013, 189: e493. DOI: 10.1016/j.juro.2013.02.2557.
- Leapman M. Hematuria After Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s410. DOI: 10.1016/j.ijrobp.2012.07.1086.
- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
Biography
Michael S. Leapman, MD, who specializes in prostate, bladder, testicular and kidney cancers, loves his work as a urologic oncologist.
“Every day, I have the ability to make a difference in a patient's life,” says Dr. Leapman. “It's a tremendous honor and responsibility, and it's very rewarding.”
A member of Yale Cancer Center, he sees patients at Smilow Cancer Hospital and the West Haven Veteran’s Administration. An assistant professor of urology at Yale School of Medicine, he studies the best treatments for prostate cancer and how gene expression signatures can predict the aggressiveness of this cancer.
“Hearing the emotionally wrought words ‘it’s cancer’ is extremely difficult to navigate,” he says. “So that's one of the issues that we are sensitive to, and continue to strive to improve.”
The patient-physician bond is essential in helping patients with prostate cancer, for example, to choose which kind of treatment is best: surgery, radiation therapy or active surveillance, an ongoing monitoring of what can be a slow-progressing disease.
“It really is a very special relationship between a urologist and a patient. I have found that the team at Yale is 100 percent invested in the outcomes of our patients, and we stand out by seeking to understand their concerns, goals by being there for them every step of the way.”
Titles
- Associate Professor of Urology
- Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
- Assistant Professor, Chronic Disease Epidemiology
Education & Training
- MHSYale University (2022)
- FellowshipUniversity of California San Francisco (2016)
- ResidencyMount Sinai Medical Center (2014)
- InternshipMount Sinai Medical Center (2010)
- MDUniversity of Maryland School of Medicine (2009)
- BACornell University (2005)
Additional Information
- John N. Forrest Jr. Prize for Mentorship in Student Research: (2022)
- Best Poster: European School of Oncology, Conference on Active Surveillance (2016)
- Merit Award: Conquer Cancer Foundation of the American Society of Clinical Oncology (2015)
- First Place Essay, History Section: American Urological Association Western Section (2015)
- Joseph F. McCarthy Physician Essay Contest, Third Place: American Urological Association Western Section (2015)
- Outstanding Abstract Selected for Oral Presentation: University of California San Francisco (2015)
- Resident Publication Award: Mount Sinai Medical Center, Department of Urology (2014)
- Resident Travel Award: Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (2013)
- AB of Urology, Urology (2018)
- Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. DOI: 10.37349/etat.2024.00269.
- Rabil M, Leapman M, Cavallo J. Reply to Editorial Comment on "Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy". Urology 2024 PMID: 39208938, DOI: 10.1016/j.urology.2024.08.054.
- Forman R, Long J, Westvold S, Agnish K, Mcmanus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.
- Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.
- Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.
- Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 101097upj0000000000000679. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy. Urology 2024 PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.
- Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024 PMID: 38959160, DOI: 10.1089/sur.2024.107.
- Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-Insured Patients with Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024 PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.
- Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.
- Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.
- Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.
- Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Leapman M, Cavallo J. MP33-06 ASSOCIATION BETWEEN CROWD-SOURCED ASSESSMENT OF TECHNICAL SKILLS (CSATSTM) AND COMPLICATIONS FOLLOWING RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e562. DOI: 10.1097/01.ju.0001009520.30626.80.06.
- Rabil M, Jalfon M, Heckscher D, Kong V, Golos A, Richmond R, Chess A, Leapman M, Cavallo J. MP02-19 AUTOMATED ABSTRACTION ALGORITHM FOR RADICAL PROSTATECTOMY SURGICAL OUTCOMES. Journal Of Urology 2024, 211: e20. DOI: 10.1097/01.ju.0001008600.97797.3b.19.
- Lokeshwar S, Choksi A, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Brito J, Renzulli J, Leapman M. MP58-01 A RANDOMIZED CONTROLLED TRIAL OF A FERMENTED SOY BEVERAGE AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER PRIOR TO RADICAL PROSTATECTOMY. Journal Of Urology 2024, 211: e947. DOI: 10.1097/01.ju.0001008852.83523.41.01.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- Webb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- Golos A, Nie J, Hsiang W, Davies B, Filson C, Leapman M. MP24-10 TRENDS IN UROLOGY PRACTICE CONSOLIDATION AND PRIVATE EQUITY INVESTMENT FROM 2011-2023. Journal Of Urology 2024, 211: e396. DOI: 10.1097/01.ju.0001008860.46052.c4.10.
- Lokeshwar S, Shaheen D, Choksi A, Patel M, Rahman S, Martin T, Hesse D, Leapman M. HF01-10 UROLOGIC EDUCATION AT THE TURN OF THE 20TH CENTURY: A STUDENT’S PERSPECTIVE. Journal Of Urology 2024, 211: e282. DOI: 10.1097/01.ju.0001008828.35887.de.10.
- Sutherland R, Golos A, Leapman M. PD40-09 “WHAT DO YOU MEAN BY a ‘RISK’? I’D LIKE TO SEE THAT PRESENTED BETTER”: A QUALITATIVE STUDY EXPLORING PATIENT PREFERENCES ABOUT PROSTATE CANCER RISK ASSESSMENT AND COMMUNICATION. Journal Of Urology 2024, 211: e823. DOI: 10.1097/01.ju.0001009356.04608.d5.09.
- Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.
- Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.
- Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
- Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Kim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy. Prostate International 2024, 12: 70-78. PMID: 39036758, PMCID: PMC11255894, DOI: 10.1016/j.prnil.2024.01.002.
- Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.
- Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar M, Pantel H, Berger E, Boffa D, Cavallo J, Leapman M. Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer 2023, 9: e45518. PMID: 37917149, PMCID: PMC10654905, DOI: 10.2196/45518.
- Heckscher D, Jalfon M, Buck M, Abello A, Nguyen J, Casilla-Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Kenney P, Cavallo J, Lambert S. Implementation of a health system intervention to reduce time from presentation to surgical intervention for pediatric testicular torsion. Journal Of Pediatric Urology 2023, 20: 254.e1-254.e7. PMID: 38030428, DOI: 10.1016/j.jpurol.2023.10.042.
- Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.
- Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.
- Leapman M. Embracing Challenges and Opportunities Posed by New Technologies in Urologic Care. Urology Practice 2023, 11: 7-8. PMID: 37747948, DOI: 10.1097/upj.0000000000000459.
- Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancerLeapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.
- Ślusarczyk A, Baboudjian M, Zapała P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas J, Życzkowski M, Karakiewicz P, Radziszewski P, Leapman M, Shariat S, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations. The Prostate 2023, 83: 1504-1515. PMID: 37545342, DOI: 10.1002/pros.24609.
- Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Jalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.
- Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.
- Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.
- Smani S, Novosel M, Marks V, Jeong F, Sprenkle P, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Journal Of Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENT. Journal Of Urology 2023, 209: e586. DOI: 10.1097/ju.0000000000003286.07.
- Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
- Leapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
- Esmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
- Laditi F, Nie J, Marks V, Leapman M. MP77-14 PATIENT AND FACILITY FACTORS ASSOCIATED WITH 90-DAY MORTALITY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2023, 209: e1107. DOI: 10.1097/ju.0000000000003351.14.
- Laditi F, Nie J, Hsiang W, Umar W, Haleem A, Marks V, Buck M, Leapman M. MP75-07 ACCESS TO UROLOGIC CANCER CARE FOR MEDICAID-INSURED PATIENTS. Journal Of Urology 2023, 209: e1081. DOI: 10.1097/ju.0000000000003349.07.
- Leapman M, Loeb S, Cooperberg M, Catalona W, Gaylis F. A vision for closing the evidence-practice gap in the management of low-grade prostate cancer. JNCI Cancer Spectrum 2023, 7: pkad028. PMID: 37101361, PMCID: PMC10133397, DOI: 10.1093/jncics/pkad028.
- Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2023, 41: 610-610. DOI: 10.1200/jco.2023.41.6_suppl.610.
- Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D, Leapman M. “It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance. Journal Of Clinical Oncology 2023, 41: 334-334. DOI: 10.1200/jco.2023.41.6_suppl.334.
- Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.
- Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.
- Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.
- Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.
- Laditi F, Nie J, Hsiang W, Umer W, Haleem A, Marks V, Buck M, Leapman M. Access to urologic cancer care for Medicaid-insured patients. Urologic Oncology Seminars And Original Investigations 2023, 41: 206.e21-206.e27. PMID: 36740488, DOI: 10.1016/j.urolonc.2023.01.014.
- Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023, 115: 413-420. PMID: 36629492, PMCID: PMC10086629, DOI: 10.1093/jnci/djad002.
- Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology 2023, 83: 463-471. PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.
- Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.
- Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.
- Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.
- Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.
- Nabavizadeh B, Li KD, Hakam N, Shaw NM, Leapman MS, Breyer BN. Incidence of circumcision among insured adults in the United States. PLOS ONE 2022, 17: e0275207. PMID: 36251658, PMCID: PMC9576047, DOI: 10.1371/journal.pone.0275207.
- Marks VA, Hsiang WR, Nie J, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Berger ER, Boffa DJ, Leapman MS. Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis. JAMA Network Open 2022, 5: e2222214. PMID: 35838668, PMCID: PMC9287756, DOI: 10.1001/jamanetworkopen.2022.22214.
- Leapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
- Rahman S, Syed J, Lokeshwar S, Press B, Monaghan T, Leapman M. MP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT. Journal Of Urology 2022, 207: e680. DOI: 10.1097/ju.0000000000002600.14.
- Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Overcash M, Sherman J. MP30-14 ENVIRONMENTAL IMPACT OF TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY. Journal Of Urology 2022, 207: e483. DOI: 10.1097/ju.0000000000002573.14.
- Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
- Khajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Journal Of Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
- Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.
- Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
- Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- Holler J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice 2021, 9: 56-63. PMID: 37145560, DOI: 10.1097/upj.0000000000000275.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Reply by Authors. Urology Practice 2021, 9: 24-24. PMID: 37145588, DOI: 10.1097/upj.0000000000000269.02.
- Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Urology Practice Acquisitions by Private Equity Firms from 2011–2021. Urology Practice 2021, 9: 17-24. PMID: 37145557, DOI: 10.1097/upj.0000000000000269.
- Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.
- Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.
- Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRI. Journal Of Urology 2021, 206: e751-e751. DOI: 10.1097/ju.0000000000002060.08.
- Fero K, Lec P, Sharma V, Lenis A, Low J, Litwin M, Leapman M, Chamie K. MP40-13 WHEN IS A SEMINOMA NOT A SEMINOMA? THE INCIDENCE, RISK FACTORS AND MANAGEMENT OF PATIENTS WITH TESTICULAR SEMINOMA WITH DISCORDANT ELEVATED SERUM ALPHA-FETOPROTEIN. Journal Of Urology 2021, 206: e719-e719. DOI: 10.1097/ju.0000000000002055.13.
- Sharma V, Lec P, Fero K, Lenis A, Shirk J, Venkataramana A, Leapman M, Chamie K, Saigal C, Litwin M. MP40-10 TESTICULAR TUMOR SIZE IS ASSOCIATED WITH NONLOCALIZED DISEASE AT DIAGNOSIS. Journal Of Urology 2021, 206: e718-e718. DOI: 10.1097/ju.0000000000002055.10.
- Buck M, Nguyen J, Abello A, Leapman M, Cavallo J, Kenney P. PD38-07 ANTIBIOTIC PROPHYLAXIS PRIOR TO OUTPATIENT UROLOGIC PROCEDURES: OUTCOMES FROM A DEPARTMENT-WIDE QUALITY IMPROVEMENT PROJECT. Journal Of Urology 2021, 206: e664-e665. DOI: 10.1097/ju.0000000000002048.07.
- Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Paradysz A, Pradere B, Shariat S, Leapman M. MP67-24 ASSESSING ONLINE CROWDFUNDING FOR UROLOGIC CANCER CARE USING AUTOMATED DATA EXTRACTION. Journal Of Urology 2021, 206: e519-e519. DOI: 10.1097/ju.0000000000002028.24.
- Demkowicz P, Buck M, Nie J, Marks V, Leapman M. MP17-03 FACILITY-LEVEL FACTORS ASSOCIATED WITH DECREASING SHARE OF UROLOGIC CANCER PATIENTS WITH MEDICAID FOLLOWING IMPLEMENTATION OF THE AFFORDABLE CARE ACT. Journal Of Urology 2021, 206: e308-e309. DOI: 10.1097/ju.0000000000002002.03.
- Leapman M, Wang R, Gross C, Ma X. PD50-11 CHANGES IN PSA SCREENING RELATIVE TO THE REVISED USPSTF GUIDANCE FOR PROSTATE CANCER SCREENING. Journal Of Urology 2021, 206: e856-e856. DOI: 10.1097/ju.0000000000002072.11.
- Press B, Khajir G, Olawoyin O, Leapman M, Sprenkle P. MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSY. Journal Of Urology 2021, 206: e468-e468. DOI: 10.1097/ju.0000000000002023.14.
- Nguyen J, Buck M, Abello A, Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Cavallo J, Kenney P, Lambert S. PD38-10 AN INITIATIVE TO REDUCE DOOR TO INCISION TIME FOR PATIENTS WITH TESTICULAR TORSION. Journal Of Urology 2021, 206: e666-e666. DOI: 10.1097/ju.0000000000002048.10.
- Lokeshwar S, Syed J, Amin J, Merenda C, Leapman M, Weiss R. HF02-11 DR. CLYDE LEROY DEMING: VISIONARY DURING A TURBULENT TIME. Journal Of Urology 2021, 206: e240-e240. DOI: 10.1097/ju.0000000000001993.11.
- Segal D, Drew I, Buck M, Grimshaw A, Cavallo J, Leapman M. HF01-14 ANALYSIS OF ETIOLOGIC THEORIES PROPOSED TO EXPLAIN RACIAL DISPARITY IN PROSTATE CANCER OUTCOMES: A SCOPING REVIEW. Journal Of Urology 2021, 206: e232-e233. DOI: 10.1097/ju.0000000000001992.14.
- Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Paradysz A, Pradere B, Shariat S, Leapman M. P0977 Assessing online crowdfunding for urologic cancer care using automated data extraction. European Urology 2021, 79: s1377. DOI: 10.1016/s0302-2838(21)01350-6.
- Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.
- Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.
- Marks V, Hsiang W, Nie J, Buck M, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Access to cancer care for Medicaid patients at cancer hospitals in the United States. Journal Of Clinical Oncology 2021, 39: 6548-6548. DOI: 10.1200/jco.2021.39.15_suppl.6548.
- Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Accessibility of Telehealth services for cancer care at cancer hospital in the United States. Journal Of Clinical Oncology 2021, 39: 6535-6535. DOI: 10.1200/jco.2021.39.15_suppl.6535.
- Miccio J, Talcott W, Jairam V, Park H, Yu J, Leapman M, King M, Nguyen P, Kann B. Quantifying Treatment Selection Bias Effects on Survival in National Database Studies: Findings from Low-Risk Prostate Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e397. DOI: 10.1016/j.ijrobp.2020.07.2439.
- Abello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
- Abello A, Renzulli J, Park H, Leapman M, Kenney P. PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer. European Urology Open Science 2020, 19: e2283. DOI: 10.1016/s2666-1683(20)34148-3.
- Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.
- Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.
- Hsiang* W, Elftmann E, Honig S, Leapman M. PD28-04 EVALUATION OF ONLINE TELEHEALTH PLATFORMS FOR DIRECT-TO-CONSUMER TREATMENT OF ERECTILE DYSFUNCTION. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000892.04.
- Leapman* M, Wang R, Ma X, Gross C. MP23-17 ASSOCIATIONS OF REGIONAL-LEVEL ADOPTION OF PROSTATE MRI AND GENOMIC TESTING AND OBSERVATION FOR PROSTATE CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000856.017.
- Abello* A, Nawaf C, Renzulli J, Park H, Leapman M, Kenney P. PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000965.02.
- Abello* A, Nawaf C, Leapman M, Kenney P. MP68-05 CLINICAL OUTCOMES OF LOW-STAGE SARCOMATOID RENAL CELL CARCINOMA. Journal Of Urology 2020, 203: e1036. DOI: 10.1097/ju.0000000000000948.05.
- Abello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
- Hsiang* W, Yousman L, Leapman M. MP12-17 ASSOCIATION OF INSURANCE STATUS AND ACCESS TO UROLOGICAL CARE AT URGENT CARE CENTERS. Journal Of Urology 2020, 203: e151. DOI: 10.1097/ju.0000000000000832.017.
- Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
- Advani S, Gao C, Datta R, Sann L, Smith C, Leapman MS, Hittelman A, Sabetta J, Dembry LM, Martinello RA, Juthani-Mehta M. Knowledge and Practices of Physicians and Nurses related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines. Open Forum Infectious Diseases 2019, 6: ofz305. PMID: 31375836, PMCID: PMC6677670, DOI: 10.1093/ofid/ofz305.
- Mehal W, Secor E, Weiss T, Fields M, Leapman M, Ali A. Isoflavone Stability Quality Control Assessment of Q-CAN® Plus, a Novel Fermented Soy Beverage (P12-034-19). Current Developments In Nutrition 2019, 3: 3013530. PMCID: PMC6574992, DOI: 10.1093/cdn/nzz035.p12-034-19.
- Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.
- Abello* A, Syed J, Leapman M, Kenney P. MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOME. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557554.82490.aa.
- Hsiang W, Jemal A, Nguyen K, Shuch B, Park H, Yu J, Gross C, Davidoff A, Leapman* M. MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557551.36748.5c.
- Javier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
- Syed* J, Abello A, Javier-DesLoges J, Leapman M, Kenney P. PD58-05 UROLOGIC MALIGNANCIES: A COMPARISON OF OUTCOMES AFTER INDEX SURGERY BETWEEN ACADEMIC AND COMMUNITY HOSPITALS. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557173.74355.7e.
- Abello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
- Yang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
- Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.
- Syed J, Abello A, Javier-Desloges J, Leapman M, Kenney P. Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals. Journal Of Clinical Oncology 2019, 37: 489-489. DOI: 10.1200/jco.2019.37.7_suppl.489.
- Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.
- Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.
- Abello A, Kenney P, Leapman M. Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy. Journal Of Clinical Oncology 2019, 37: 284-284. DOI: 10.1200/jco.2019.37.7_suppl.284.
- Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate CancerLeapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.
- Javier-DesLoges J, Amirkhiz K, Su J, Kenney P, Advani S, Hittelman A, Leapman M. MP80-02 LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTION. Journal Of Urology 2018, 199: e1089. DOI: 10.1016/j.juro.2018.02.2690.
- Masic S, Nguyen H, Cowan J, Leapman M, Carroll P. PD38-10 IMPACT OF LYMPH NODE COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN NODE POSITIVE PATIENTS WITH PROSTATE CANCER. Journal Of Urology 2018, 199: e740. DOI: 10.1016/j.juro.2018.02.1757.
- Hsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Journal Of Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
- Leapman M, Wang R, Park H, Yu J, Gross C, Ma X. MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT. Journal Of Urology 2018, 199: e707. DOI: 10.1016/j.juro.2018.02.1679.
- Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
- Amirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
- Amirkhiz K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. PD42-01 NATIONAL TRENDS IN THE MANAGEMENT OF PATIENTS WITH POSITIVE SURGICAL MARGINS AT THE TIME OF RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e814. DOI: 10.1016/j.juro.2018.02.1954.
- Lu A, Amirkhiz K, Nguyen K, Hsiang W, Leapman M. MP34-07 DISPARITIES IN THE DIAGNOSIS AND MANAGEMENT OF METASTATIC PROSTATE CANCER IN YOUNG MEN. Journal Of Urology 2018, 199: e440. DOI: 10.1016/j.juro.2018.02.1099.
- Nguyen K, Nolte A, Alimi O, Hsiang W, Syed J, Suarez-Sarmiento A, Lu A, Ghabili K, Shuch B, Leapman M. PD51-06 DETERMINANTS OF ACTIVE SURVEILLANCE IN PATIENTS WITH SMALL RENAL MASSES. Journal Of Urology 2018, 199: e977-e978. DOI: 10.1016/j.juro.2018.02.2346.
- Su J, Javier-DesLoges J, Leapman M. MP51-09 EXAMINING POST-OPERATIVE OPIOID PRESCRIBING PATTERNS FOLLOWING UROLOGIC SURGERY USING AN ENTERPRISE-WIDE ELECTRONIC MEDICAL RECORD. Journal Of Urology 2018, 199: e688. DOI: 10.1016/j.juro.2018.02.1640.
- Nguyen K, Hsiang W, Syed J, Nolte A, Lu A, Suarez-Sarmiento A, Ghabili K, Shuch B, Leapman M. MP10-14 INCIDENCE, RISK FACTORS, AND OUTCOMES OF C. DIFFICILE INFECTION FOLLOWING RADICAL CYSTECTOMY: A NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (NSQIP) STUDY. Journal Of Urology 2018, 199: e122. DOI: 10.1016/j.juro.2018.02.360.
- Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e1066. DOI: 10.1016/j.juro.2018.02.2644.
- Lu A, Nguyen K, Nolte A, Alimi O, Hsiang W, Ghabili K, Syed J, Shuch B, Leapman M. National determinants of active surveillance among patients with clinical stage 1A kidney tumors. Journal Of Clinical Oncology 2018, 36: 694-694. DOI: 10.1200/jco.2018.36.6_suppl.694.
- Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
- Ghabili K, Nguyen K, Lu A, Hsiang W, Shuch B, Leapman M. Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 144-144. DOI: 10.1200/jco.2018.36.6_suppl.144.
- Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
- Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.
- Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
- Ghabili K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. National trends in the management of patients with positive surgical margins at the time of radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 111-111. DOI: 10.1200/jco.2018.36.6_suppl.111.
- Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLOS ONE 2017, 12: e0185535. PMID: 29016610, PMCID: PMC5634556, DOI: 10.1371/journal.pone.0185535.
- Nguyen K, Gross C, Cooperberg M, Katz M, Hittelman A, Syed J, Schulam P, Leapman M. MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT? Journal Of Urology 2017, 197: e928-e929. DOI: 10.1016/j.juro.2017.02.2303.
- Eapen R, Washington S, Sanford T, Leapman M, Meng M, Porten S. MP10-13 IMPACT OF HISTOLOGIC SUBTYPE ON BLADDER CANCER OUTCOME. Journal Of Urology 2017, 197: e113. DOI: 10.1016/j.juro.2017.02.341.
- Nguyen H, Westphalen A, Niloufar A, Leapman M, Cowan J, Simko J, Shinohara K, Carroll P. PD65-11 DOES PI-RADS V2 SCORES PREDICT ADVERSE SURGICAL PATHOLOGY AT RADICAL PROSTATECTOMY? Journal Of Urology 2017, 197: e1270. DOI: 10.1016/j.juro.2017.02.2961.
- Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.
- Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.
- Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer OutcomesLeapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.
- Leapman M, Carroll P. Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. Urology Practice 2016, 4: 322-328. PMID: 37592678, DOI: 10.1016/j.urpr.2016.06.008.
- Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.
- Eltemamy M, Leapman M, Cowan J, Shinohara K, Westphalen A, Carroll P. MP15-07 SERIAL ANATOMIC PROSTATE ULTRASOUND IMAGING DURING PROSTATE CANCER ACTIVE SURVEILLANCE. Journal Of Urology 2016, 195: e154. DOI: 10.1016/j.juro.2016.02.2531.
- Leapman M, Nguyen H, Cowan J, Porten S, Meng M, Cooperberg M, Carroll P. MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER. Journal Of Urology 2016, 195: e1043. DOI: 10.1016/j.juro.2016.02.2033.
- Leapman M, Wang Z, Behr S, Kurhanewicz J, Zagoria R, Carroll P, Guimarães C, Westphalen A. MP79-10 PROTON MAGNETIC RESONANCE IMAGING SPECTROSCOPY IMPROVES PREDICTION OF HIGH GRADE PROSTATE CANCER WHEN INTEGRATED IN PI-RADS 2. Journal Of Urology 2016, 195: e1038. DOI: 10.1016/j.juro.2016.02.2008.
- Leapman M, Nguyen H, Cowan J, Perez N, Shinohara K, Catalona W, Cooperberg M, Carroll P. PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER. Journal Of Urology 2016, 195: e56. DOI: 10.1016/j.juro.2016.02.2089.
- Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. MP79-11 EXTERNAL VALIDATION OF A PROGNOSTIC GLEASON GRADE CLASSIFICATION SYSTEM. Journal Of Urology 2016, 195: e1038-e1039. DOI: 10.1016/j.juro.2016.02.2009.
- Leapman M, Tran G, Nguyen H, Cowan J, Westphalen A, Shinohara K, Carroll P. MP15-19 FUSION MRI-ULTRASOUND BIOPSY DURING PROSTATE CANCER ACTIVE SURVEILLANCE. Journal Of Urology 2016, 195: e159. DOI: 10.1016/j.juro.2016.02.2543.
- Nguyen H, Leapman M, Punnen S, Cowan J, Cary C, Welty C, Cooperberg M, Meng M, Greene K, Porten S, Garcia M, Carroll P. PI-03 A RANDOMIZED STUDY OF INTRA-OPERATIVE AUTOLOGOUS RETROPUBIC URETHRAL SLING ON URINARY CONTROL AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY. Journal Of Urology 2016, 195: e409-e410. DOI: 10.1016/j.juro.2016.02.1208.
- Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Walker K, Amling C, Carroll P, Cooperberg M. PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACY. Journal Of Urology 2016, 195: e987-e988. DOI: 10.1016/j.juro.2016.02.1755.
- Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. External validation of a prognostic Gleason grade classification system. Journal Of Clinical Oncology 2016, 34: 123-123. DOI: 10.1200/jco.2016.34.2_suppl.123.
- Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.
- Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.
- Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.
- Nguyen H, Leapman M, Cowan J, Carroll P. Extended lymphadenectomy: A critical review. European Urology Open Science 2016, 15: 33-33c. DOI: 10.1016/s1569-9056(16)30007-0.
- Leapman M, Nguyen H, Cowan J, Carroll P. Are there any new reliable triggers in active surveillance? European Urology Open Science 2016, 15: 31-31b. DOI: 10.1016/s1569-9056(16)30005-7.
- Leapman M, Cooperberg M. Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined? 2016, 33-52. DOI: 10.1007/978-3-319-21485-6_3.
- Leapman M, Shinohara K. TRUS Biopsy: Is There Still a Role? 2016, 53-67. DOI: 10.1007/978-3-319-21485-6_4.
- Polland A, Leapman M, Stone N. A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate Cancer. 2015, 151-172. DOI: 10.1007/978-3-319-23817-3_11.
- Garcia M, Leapman M, Brajtbord J, Carroll P. PD15-12 DESIGN AND EARLY CLINICAL EXPERIENCE WITH A TACTILE FEEDBACK DRIVEN PELVIC FLOOR MUSCLE TRAINING SMARTPHONE APP. Journal Of Urology 2015, 193: e329. DOI: 10.1016/j.juro.2015.02.1329.
- Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo P, Cooperberg M, Carroll P. MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA). Journal Of Urology 2015, 193: e642-e643. DOI: 10.1016/j.juro.2015.02.1712.
- Leapman M, Crawford D, Poage W, Stone N. MP24-10 DECLINING USE OF URINARY HERBAL AND VITAMIN SUPPLEMENTS AMONG U.S. MEN IN LONGITUDINAL NATIONAL PROSTATE CANCER SCREENING COHORTS. Journal Of Urology 2015, 193: e279. DOI: 10.1016/j.juro.2015.02.1152.
- Leapman M, Shinohara K, Ameli N, Meng M, Cooperberg M, Carroll P. MP86-10 CLINICAL PROSTATE CANCER RISK PREDICTION DERIVED FROM TARGETED BIOPSY. Journal Of Urology 2015, 193: e1079. DOI: 10.1016/j.juro.2015.02.1919.
- Welty C, Leapman M, Brajtbord J, Cowan J, Cooperberg M, Carroll P. PD47-02 IMPROVED PRE-RADICAL PROSTATECTOMY RISK STRATIFICATION USING PSA DENSITY. Journal Of Urology 2015, 193: e961-e962. DOI: 10.1016/j.juro.2015.02.2746.
- Sagalovich D, Leapman M, Sfakianos J, Hall S, Stock R, Stone N. MP87-04 TIMING OF SALVAGE ANDROGEN DEPRIVATION THERAPY FOLLOWING PROSTATE RADIOTHERAPY DOES NOT ADVERSELY AFFECT ALL-CAUSE OR PROSTATE CANCER SPECIFIC SURVIVAL. Journal Of Urology 2015, 193: e1085. DOI: 10.1016/j.juro.2015.02.1949.
- Leapman M, Ameli N, Chu C, Hussein A, Welty C, Cooperberg M, Carroll P. MP42-12 CANCER OF THE PROSTATE RISK ASSESSMENT SCORE FOLLOWING BIOPSY GLEASON UPGRADE DURING PROSTATE CANCER ACTIVE SURVEILLANCE IS ASSOCIATED WITH ADVERSE PATHOLOGY AT PROSTATECTOMY. Journal Of Urology 2015, 193: e513. DOI: 10.1016/j.juro.2015.02.1597.
- Leapman M, Westphalen A, Ameli N, Lawrence H, Febbo P, Cooperberg M, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal Of Clinical Oncology 2015, 33: 83-83. DOI: 10.1200/jco.2015.33.7_suppl.83.
- Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.
- Kwon Y, Mcbride R, Leapman M, Katsigeorgis M, Collingwood S, Hobbs A, Samadi D. P046 The modulating effects of benign prostate hyperplasia medications on upgrading predictors. European Urology Open Science 2014, 13: 126. DOI: 10.1016/s1569-9056(14)61269-0.
- Collingwood S, Kwon Y, Hobbs A, Katsigeorgis M, Mcbride R, Leapman M, Samadi D. P045 The quality of nerve-sparing during radical prostatectomy affects sexual function and urinary continence recovery. European Urology Open Science 2014, 13: 125. DOI: 10.1016/s1569-9056(14)61268-9.
- Leapman M, Stock J. FRII-05 FIVE DECADES OF UROLOGIC INVESTIGATION IN MICROGRAVITY. Journal Of Urology 2014, 191: e628-e629. DOI: 10.1016/j.juro.2014.02.1743.
- Leapman M, Jayadevan R, Phillips C, Hall S, Palese M, Fischman A. V5-14 PERCUTANEOUS GAS-COOLED MICROWAVE ABLATION FOR SMALL RENAL MASSES: THE MOUNT SINAI EXPERIENCE. Journal Of Urology 2014, 191: e620. DOI: 10.1016/j.juro.2014.02.1717.
- Leapman M, Stone N. Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer. Current Bladder Dysfunction Reports 2013, 8: 236-241. DOI: 10.1007/s11884-013-0188-5.
- Leapman M, Stock J. 1115 CIRCUMCISION REVERSAL: ANTIQUITY AND THE DEFICIENT PREPUCE. Journal Of Urology 2013, 189: e456. DOI: 10.1016/j.juro.2013.02.707.
- Leapman M, Stone N, Mock S, Hall S, Stock R. 1203 PREDICTORS OF URINARY INCONTINENCE FOLLOWING PROSTATE BRACHYTHERAPY. Journal Of Urology 2013, 189: e493. DOI: 10.1016/j.juro.2013.02.2557.
- Leapman M. Hematuria After Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s410. DOI: 10.1016/j.ijrobp.2012.07.1086.
- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519
- Yale UrologyYale Physicians Building800 Howard AvenueNew Haven, CT 06519